Sugi Predict

Sugi Predict / Targets / RAET1L

RAET1L

UL16-binding protein 6 (Retinoic acid early t · Q5VY80 · RAET1L on Sugi Atlas →

2,021 patent compounds predicted against RAET1L, 513 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3919085 SCHEMBL3919085 0.64 15/20
SCHEMBL8235992 SCHEMBL8235992 0.59 15/20
SCHEMBL8235594 SCHEMBL8235594 0.46 13/20
SCHEMBL20743022 SCHEMBL20743022 0.49 11/20
SCHEMBL8227997 SCHEMBL8227997 0.47 11/20
SCHEMBL4488563 SCHEMBL4488563 0.45 11/20
SCHEMBL15388874 SCHEMBL15388874 0.51 9/20
SCHEMBL8232539 SCHEMBL8232539 0.45 9/20
SCHEMBL22048232 SCHEMBL22048232 0.38 9/20
SCHEMBL18705673 SCHEMBL18705673 0.38 8/20
SCHEMBL7745771 SCHEMBL7745771 0.57 7/20
SCHEMBL1307758 SCHEMBL1307758 0.54 7/20
SCHEMBL1309664 SCHEMBL1309664 0.53 7/20
SCHEMBL5106559 SCHEMBL5106559 0.40 7/20
SCHEMBL8234513 SCHEMBL8234513 0.50 6/20
SCHEMBL19283605 SCHEMBL19283605 0.41 6/20
SCHEMBL6850836 SCHEMBL6850836 0.55 5/20
SCHEMBL6706746 SCHEMBL6706746 0.54 5/20
SCHEMBL1308440 SCHEMBL1308440 0.53 5/20
SCHEMBL13485786 SCHEMBL13485786 0.53 5/20

Clinical trials — most relevant to RAET1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients PHASE4NOT_YET_RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer PHASE1/PHASE2COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer PHASE1/PHASE2COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer PHASE1COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma EARLY_PHASE1UNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects nanWITHDRAWN
Autophagy Bladder Cancer nanUNKNOWN
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer nanRECRUITING
Expression and Clinical Significance of IGHD in Pancreatic Cancer nanUNKNOWN
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Serum Talin-1 and Cripto-1 in Colorectal Cancer nanNOT_YET_RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Surgical Corection of Congenital Proximal Radioulnar Synostosis Using Double Osteotomy Technique. nanNOT_YET_RECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Genetic of SportS Induced Endofibrotic Remodeling nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RAET1L binder may also engage these)

ProteinNameSimilarity
Q9BZM5 — 1.000 Q9BZM5 →
Q9BZM4 — 1.000 Q9BZM4 →
Q9BZM6 — 0.999 Q9BZM6 →
Q8TD07 — 0.993 Q8TD07 →
Q6H3X3 — 0.984 Q6H3X3 →
A0A0G2K7V7 — 0.972 A0A0G2K7V7 →
Q8HWE5 — 0.971 Q8HWE5 →
MICA MHC class I polypeptide-related sequence A (M 0.966 landscape →
P07350 — 0.966 P07350 →
O08602 — 0.966 O08602 →
P09235 — 0.965 P09235 →
O08603 — 0.965 O08603 →
Q29980 — 0.965 Q29980 →
P14432 — 0.965 P14432 →
P35849 — 0.964 P35849 →
Q9JI58 — 0.964 Q9JI58 →
P01573 — 0.963 P01573 →
Q8HWE7 — 0.963 Q8HWE7 →
O08604 — 0.963 O08604 →
P07349 — 0.962 P07349 →
Q80SS5 — 0.962 Q80SS5 →
P06799 — 0.962 P06799 →
Q9CZQ6 — 0.962 Q9CZQ6 →
P60018 — 0.962 P60018 →
Q9GKZ0 — 0.961 Q9GKZ0 →
P43628 — 0.961 P43628 →
P05001 — 0.961 P05001 →
Q9GL43 — 0.961 Q9GL43 →
P81255 — 0.961 P81255 →
D3ZQX2 — 0.961 D3ZQX2 →